Anne Szostak - IDEXX Laboratories Independent Director
IDXX Stock | USD 489.57 1.72 0.35% |
Director
Ms. M. Anne Szostak is Independent Director of IDEXX Laboratories, Inc. Ms. Szostak had a 31year career with FleetBoston Financial Group, a diversified financial services company, until her retirement in 2004. She served as Chairman and Chief Executive Officer of Fleet BankRhode Island from 2001 to 2003, Chairman, President and Chief Executive Officer of FleetMaine from 1991 to 1994, and Corporationrationrate Executive Vice President and Chief Human Resources Officer of FleetBoston Financial Group from 1998 to 2004. After her retirement, Ms. Szostak founded Szostak Partners, an executive coaching and human resources consulting firm, and as President of Szostak Partners, she provides strategic advice and counsel to clients. Ms. Szostak holds an undergraduate degree from Colby College, and she has completed several executive education programs at Harvard Business School. Through her executive leadership roles at FleetBoston Financial Group, including serving as a chief executive officer of two major bank subsidiaries, Ms. Szostak brings extensive leadership, management, financial services and human resources experience to the Board. In particular, Ms. Szostak has deep expertise in human capital management, which is a key driver for our strategy of innovation since 2012.
Age | 67 |
Tenure | 12 years |
Address | One IDEXX Drive, Westbrook, ME, United States, 04092 |
Phone | 207 556 0300 |
Web | https://www.idexx.com |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Similar Executives
Showing other executives | DIRECTOR Age | ||
Christopher Reidy | Encompass Health Corp | 64 | |
Ann Blouin | The Ensign Group | 65 | |
Bryan Cressey | Select Medical Holdings | 71 | |
Harold Berger | CryoCell International | 51 | |
Edward Shaw | Encompass Health Corp | 73 | |
George Gaines | CryoCell International | 61 | |
Katherine Davisson | Select Medical Holdings | 53 | |
Thomas Scully | Select Medical Holdings | 63 | |
Arthur Ellis | CryoCell International | N/A | |
James Dalton | Select Medical Holdings | 73 | |
Ernest Burgess | National HealthCare | 79 | |
John Maupin | Encompass Health Corp | 73 | |
Marilyn Tavenner | Select Medical Holdings | 69 | |
Yvonne Curl | Encompass Health Corp | 65 | |
Jonathan Wheeler | CryoCell International | 55 | |
William Frist | Select Medical Holdings | 69 | |
Lee Daniels | The Ensign Group | 61 | |
Harold Paz | Select Medical Holdings | 62 | |
Donald Correll | Encompass Health Corp | 70 | |
Joan Herman | Encompass Health Corp | 67 | |
Paul Abernathy | National HealthCare | 82 |
Management Performance
Return On Equity | 0.81 | ||||
Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathy Turner, Corporate Vice President | ||
Sophie Vandebroek, Director | ||
Jonathan Ayers, Chairman, CEO and Pres | ||
William End, Lead Independent Director | ||
Jacqueline Studer, Corporate Vice President General Counsel, Secretary | ||
Johnny Powers, Executive VP | ||
Rebecca Henderson, Independent Director | ||
Michael Lane, Corporate Vice President General Manager | ||
Anne Szostak, Independent Director | ||
George Fennell, Senior Officer | ||
Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
Ken Grady, Senior Officer | ||
Jay Mazelsky, Executive VP | ||
Stuart Essig, Independent Director | ||
M Szostak, Independent Director | ||
Bruce Claflin, Independent Director | ||
Sam Samad, Independent Director | ||
Barry Johnson, Independent Director | ||
Giovani Twigge, Chief Human Resource Officer, Corporate Vice President | ||
Nimrata PE, Sector Strategy | ||
Martin Smith, Executive CTO | ||
Jeffery Chadbourne, Director Reporting | ||
Daniel Junius, Independent Director | ||
Lawrence Kingsley, Independent Director | ||
Kerry Bennett, Senior Labs | ||
Thomas Craig, Independent Director | ||
Michael Johnson, Executive Officer | ||
Jonathan Mazelsky, CEO President | ||
James Polewaczyk, Executive Officer | ||
John Hart, Senior Operations | ||
Michael Williams, Executive VP | ||
Pat Venters, Chief Marketing Officer, Vice President | ||
Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.81 | ||||
Return On Asset | 0.23 | ||||
Profit Margin | 0.23 % | ||||
Operating Margin | 0.27 % | ||||
Current Valuation | 41.29 B | ||||
Shares Outstanding | 83.05 M | ||||
Shares Owned By Insiders | 0.92 % | ||||
Shares Owned By Institutions | 92.56 % | ||||
Number Of Shares Shorted | 1.76 M | ||||
Price To Earning | 61.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.04 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.